Back to results
US 2015/0307586 A1Published application
Epsigam fusion protein
AssigneeTunitas Therapeutics, Inc.
InventorsNolan Sigal, Gizette Sperinde
Life of this patent
Estimating the term…
Abstract
Epsi-gam provides a novel fusion protein with the ability to cross-link either of the FcεRI or FcεRII cell surface receptors with an FcγRIIb cell surface receptor in order to block IgE-mediated biological responses.
Claims11
A method for manufacturing a fusion protein, comprising
- synthesizing a nucleotide sequence comprising of a first restriction site at a first end of the nucleotide sequence and a second restriction site at a second end of the nucleotide sequence;
- inserting the nucleotide sequence into a cloning vector;
- excising the nucleotide sequence from the cloning vector using a first restriction enzyme corresponding to said first restriction site and a second restriction enzyme corresponding to the second restriction site;
- inserting the nucleotide sequence into an expression vector, wherein said expression vector links the expression of an exogenous protein to the glutamine synthetase gene;
- transfecting cells with the expression vector using electroporation, wherein the cells are deficient in glutamine synthetase;
- incubating the transfected cells;
- and
- collecting a secreted protein from the cells comprising said fusion protein.
5 more elements
Dependencies are inferred from the claim text.